Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
Leili Gao, Byung‐Wan Lee, Manoj Chawla, Joshua Kim, Li Huo, Liying Du, Yan Huang, Linong Ji
Topics & Concepts
Insulin glargineMedicineInternal medicineMetforminType 2 diabetesInsulinClinical endpointDiabetes mellitusRandomized controlled trialGastroenterologyEndocrinologyDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and Research